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KEY MESSAGES
l	 Treatment completion rates were high; 68% of participants successfully completed 
their intake detoxification treatment programme. 
l	 (Illicit) drug abstinence rates (i.e. excluding alcohol) increased from 8% at 
treatment intake to 45% at 1-year. Abstinence from all drugs (including 
prescribed drugs) increased from 5% at treatment intake to 39% at 1-year.
l	 Participants’ use of heroin, as well as methadone (non-prescribed), 
benzodiazepines (non-prescribed), cocaine and alcohol reduced at 1-year, in 
terms of the numbers reporting use, their frequency of use and the average 
quantity of each drug consumed.
l	 Overall, a higher proportion of participants reported no involvement in crime at  
1-year (74%) compared to treatment intake (19%). Levels of involvement in 
crime reduced across six of the 12 categories of offences. 
l	 Decreases in the number of participants who had injected (from 48% to 23%)  
and in the frequency of injecting were reported at 1-year.
l	 Improvements in physical health symptoms were observed at 1-year, in particular  
those associated with opiate withdrawal. The most notable improvements in 
mental health were observed in anxiety-related symptoms. 
l	 The mortality rate for the cohort was 1.2% (1/81).
l	 Increase in contact with a range of medical and social care services were reported. 
l	 At 1-year follow-up, 73% of participants were in some form of treatment; 42% 
were on prescribed methadone. 
Detoxification Modality
Structured detoxification is a process whereby individuals are systematically and safely 
withdrawn from opiates, under medical supervision. The most common method of 
opiate detoxification in Ireland is to use methadone and slowly taper the dose down 
to zero over a period of time. Structured detoxification programmes are provided in 
both inpatient and outpatient facilities and can vary in duration from approximately 
4-12 weeks.
ROSIE study recruitment was carried out in the three dedicated inpatient facilities for 
problem drug users in Ireland; two statutory facilities located within hospital settings 
in Dublin (i.e. a purpose-built unit and a ward off the psychiatric wing of a large city 
hospital) and a non-statutory unit located outside Dublin city. In addition, recruitment 
was carried out in one community-based outpatient facility, providing a supervised, 
structured programme. Finally, recruitment also occurred in the detoxification 
programme provided within Mountjoy Prison – the Medical Unit.
In summary, 56% (n=45) of the ROSIE detoxification cohort were recruited from 
inpatient settings, 27% (n=22) from outpatient settings and 17% from the prison 
setting (n=14).
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Research Outcome Study in Ireland 
(ROSIE)
The Research Outcome Study in Ireland (ROSIE) is the 
first national, prospective, longitudinal, multi-site drug 
treatment outcome study in the country. The National 
Advisory Committee on Drugs (NACD) commissioned 
this research in 2002 as required by the National 
Drugs Strategy Action 99. The aim of the Study is to 
recruit and follow opiate users entering treatment over 
a period of time documenting the changes observed. 
The contract was awarded to Dr Catherine Comiskey 
and NUI Maynooth.
The ROSIE study follows participants from the point 
of commencing a new treatment episode (treatment 
intake) and monitors progress at time-anchored points; 
6 months, 1-year and 3-years after treatment intake. 
Between September 2003 and July 2004, the ROSIE 
study recruited 404 opiate users on entry into three-
index treatments; methadone maintenance/reduction 
(53.2%, n=215) structured detoxification (20%, 
n=81) and abstinence-based treatment (20.3%, 
n=82). In addition, a sub-sample of opiate users were 
recruited from needle-exchanges (6.4%, n=26).These 
modalities were part of the tender brief from the 
NACD as they were considered to represent the most 
widely implemented interventions for opiate users in 
Ireland.
Detoxification cohort: Follow-up rates
Of the 81 people recruited within the detoxification 
modality, 93% (n=75) were located, and 77% 
(n=62) successfully completed a 1-year interview. One 
individual died within the follow-up period, four people 
withdrew from the study, eight people were located 
but not successfully interviewed, and an additional six 
participants were not located. These 19 people ‘lost’ to 
follow-up were excluded from the comparative analysis 
to allow for valid assessment across the two time 
periods.This is the second paper in the ROSIE Findings 
series and it provides a snapshot of the outcomes for 
people in the detoxification modality one year after 
treatment intake.
SUMMARY OF 1-YEAR OUTCOMES
DETOXIFICATION MODALITY
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METHODOLOGY
1. Study design
The 404 ROSIE study participants were recruited from both inpatient (hospital, residential programmes & prisons) and outpatient settings 
(community-based clinics, health board clinics & GPs). Participants had to be over 18 years, commencing a new treatment episode, 
prepared to consent to the tracking/follow-up procedures, and willing to provide locator information. Treatment agencies participating in 
the study were purposively (not randomly) sampled to reflect drug treatment in Ireland, and the known geographical spread of provision 
and range of services. In total, 44 agencies providing approximately 54 services located in rural, urban and inner-city areas of Ireland were 
involved in the study. In addition, a Research Advisory Group was established by the NACD to support and monitor the research project.
Participants were interviewed at the three time-periods using a pre-prepared interview schedule which examined key outcome measures 
including:
l	 Drug use (drug type, frequency, cost and quantity of drug use)
l	 General health (a 10-point physical & mental health assessment)
l	 Social functioning (employment, accommodation, involvement in crime)
l	 Harm (injecting behaviour & experience of overdose)
l	 Mortality (participant/contact feedback & checking non-followed-up participants against the General Death Register).
In addition to a lifetime measure, measures were taken of behaviours in the 90 days preceding interviews, except for injecting-related risk 
behaviour variables when 30 days was used. Individuals were asked about their use of 16 substances. This document focuses on the 
seven most frequently reported problem drugs – referred to as target drugs – (i.e. heroin, methadone (non-prescribed), benzodiazepines 
(non-prescribed), cocaine powder, crack cocaine, cannabis & alcohol) and reports changes in use patterns at 1-year.
2. Follow-up
Follow-up of participants was assisted by the provision of at least four contacts (locator information) for each person (including a drug 
treatment contact, family member, GP & others). A small remuneration was provided at 1-year follow-up to acknowledge the ongoing 
participation of the individual in the study.
3. Study limitations
1. Although the findings presented here highlight positive outcomes for study participants, they do not indicate a direct causal 
relationship between the treatment received and the outcomes observed.
2. The study did not randomly allocate participants to treatment settings/modality or employ a control group (drug users with similar 
profiles not attending the index treatment).
3. Any individual behaviour change is the result of the interaction of three factors, the person, the environment and the intervention, all 
of which can influence outcomes but could not be controlled for in this study.
4. Understanding this paper
Data are presented on the 62 individuals recruited within the detoxification modality who completed treatment intake and 1-year follow-
up interviews. Only individuals who provided valid answers to each individual question at the two time periods were included in the 
analysis. Missing data were handled by excluding the cases from the particular analysis. Changes in categorical variables were analysed 
using the McNemar test. When the results of these tests were found to be statistically significant1 an asterisk (*) was inserted into the 
frequency tables and/or graphs. Full details of these tests will form part of the ROSIE Study Technical Report on 12-month Outcomes. 
Percentages are rounded up. Comparisons of means were analysed using paired-sample t-tests (‡ indicates statistical significance).
5. ROSIE Findings Series
• ROSIE Findings 1 reported on the 1-year outcomes for the followed-up population (n=305) across all modalities.
• ROSIE Findings 2 (this paper) presents 1-year outcomes for individuals recruited within the detoxification modality.
• ROSIE Findings 3 will present 1-year outcomes for individuals recruited within the abstinence modality.
• ROSIE Findings 4 will present 1-year outcomes for individuals recruited within the methadone modality.
Further issue-based papers will be published in due course.
1  Statistical significance can only be stated when tests have been carried out on the data to establish the degree of confidence with which we can 
infer that the differences in the observed findings are true and not due to sampling or other error. This is usually reported at a 5% level of probability 
which means where a p value is found to be less than or equal to 0.05 we can be confident that 95 times out of 100 the outcomes and differences 
observed are not due to chance.
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Profile of Participants at  
Treatment Intake
The demographic characteristics of the detoxification participants 
(n=81) are presented in Table 1. The treatment entrants were 
typically males, on average 26 years-of-age and largely reliant on 
social welfare payments. Less than half the cohort were parents 
of children under 18 years-of-age, the majority of whom (62%) 
did not have their children in their care. Most of the entrants had 
spent some time in prison, and 11% were homeless in the 90 
days prior to treatment intake interview.
Table 1 Demographic profile of participants
Gender (% male) 77
Average age (yrs) 26
a Early school leavers (%) 37
b Specified main source of income (%)
  Social welfare 73
  Employed 15
b Homeless (%) 11
Ever in prison (%) 70
Parents (%) 47
a Defined as leaving school before 16 years, or before completion of 
three years of post-primary education (Education, Welfare Act 2000)
b In the 90 days prior to treatment intake
Treatment Completion Rates
Figure 1 shows that the treatment completion rate was high; the 
majority of participants (68%) successfully completed their intake 
treatment. Just over one-quarter of the cohort dropped out of 
treatment before programme completion and 5% of participants 
transferred to another treatment-type before finishing the intake 
detoxification programme.
Figure 1 Treatment completion rates at 1-year
Dropped out 
of treatment 
27% 
(n=17)
Completed
Treatment 
68% (n=42)
Transferred 
to other 
treatment
5% (n=3)
Treatment Status at 1-year
One year after treatment intake, 73% of participants reported 
being in some form of drug treatment. Forty-two percent of 
participants were on a methadone programme and approximately 
one-third (34%) of the cohort were attending one-to-one 
counselling (see Table 2). Almost one-quarter (24%) of 
participants were attending group work; this category includes 
Narcotics Anonymous (NA) meetings, aftercare programmes,  
and structured day programmes.
Table 2 Treatment category at 1-year interview
a Treatment at 1-year % n
Currently in Treatment 73 45
Methadone maintenance/reduction 42 26
Detoxification programme 2 1
Residential rehabilitation 5 3
One-to-one counselling 34 21
Group Work 24 15
a Percentages do not sum to 100, as categories are not mutually 
exclusive
Drug Use Outcomes
The number of people who reported using heroin, methadone 
(non-prescribed), benzodiazepines (non-prescribed), cocaine, 
cannabis and alcohol in the 90 days prior to interview decreased 
between treatment intake and 1-year follow-up (see Table 3). 
Polydrug use in the 90 days prior to interview also reduced; from 
85% (n=53) at treatment intake to 40% (n=25) at 1-year. The 
average number of days in which heroin, benzodiazepines (non-
prescribed), cocaine, cannabis and alcohol were used in the 90 
days prior to interview reduced. Non-significant reductions were 
observed in the proportions who reported crack cocaine and 
in the frequency of its use. The consumption levels of heroin, 
methadone (non-prescribed), benzodiazepines (non-prescribed), 
cocaine and alcohol decreased over the time period, as indicated 
by changes in the mean daily quantity used in the 90 days prior 
to interview.
The most substantial reduction over the follow-up period was in 
heroin use, in terms of the proportions of participants using the 
drug (79% at treatment intake compared with 39% at 1-year), 
and the frequency of use. 
Importantly, there was no increase in the reported use of 
any other substances coinciding with the decrease in heroin 
consumption.
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Table 3 Drug use in the 90 days prior to treatment intake & 1-year interview
% Used Mean days used Mean daily quantity used
Intake 1-year Intake 1-year Intake 1-year
% n % n Mean sd Mean sd Mean sd Mean sd
Heroin (grams) 79 49 39 24* 38.3 32.3 14.1 27.2 ‡ 0.5 0.6 0.1 0.3 ‡
a Methadone (mls) 49 30 11 7* 10.3 21.4 6.1 21.4 20.5 28.8 5.3 19.1 ‡
a Benzodiazepines 
(mgs)
51 31 21 13* 16.4 27.6 4.8 16.7 ‡ 31.0 58.9 8.1 31.9 ‡
Cocaine (grams) 56 35 24 15* 12.2 23.1 3.3 11.9 ‡ 1.6 3.4 0.6 1.4 ‡
Crack cocaine 15 9 5 3 1.3 5.0 0.6 3.1 nc nc nc nc
Cannabis (joints) 65 39 37 22* 37 39.7 20.1 34.6 ‡ 5.6 11.5 7.0 38.7
Alcohol (units) 61 38 40 25* 15.4 23.1 6.2 10.9 ‡ 8.6 9.8 4.4 8.1 ‡
* McNemar test revealed statistically significant changes. ‡ Paired t-test showed statistical significance. nc (not calculated) Crack cocaine was excluded from  
the analysis due to the inconsistency in the way data was reported. a Refers to the use of non-prescribed drugs.
Drug Abstinence Rates
At treatment intake only 8% (n=5) of participants reported that they 
had not used any non-prescribed drugs (excluding alcohol) in the 
preceding 90 days. By 1-year interview this had increased to 45% 
(n=28) of participants. Figure 2 illustrates this increase in illicit drug 
abstinence rates. Abstinence from all drugs, including prescribed 
methadone also increased from 5% (n=3) at intake to 39 % (n=24) 
at 1-year.
Figure 2 Illicit drug abstinence rates in 90 days prior to 
treatment intake & 1-year interview
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Average amount spent on each drug
The aforementioned changes in reported drug use were accompanied 
by the following changes in the average amount individuals spent (€) 
on a typical drug using day, on four substances:
l	 A reduction in the average daily heroin spend a from €96.70 at 
treatment intake (sd=110.50) to €21.30 at 1-year (sd=49.30)
l	 A reduction in the average daily cocaine powder spend b from 
€171.10 at treatment intake (sd=374.4) to €37.60 at 1-year 
(sd=94.7)
l	 A reduction in the average daily crack cocaine spend c from 
€30.50 at treatment intake (sd=104.2) to €1.70 at 1-year 
(sd=13.1)
l	 No changes in the average daily cannabis spend d (€2.20 at 
intake and €2.50 at 1-year).
a Based on a bag of heroin (0.113 grams) costing €20
b Based on 1 gram of cocaine powder costing €110 at intake €66 at 1-year
c Based on 1 rock costing €50 and/or the cost of cocaine powder as above
d Based on 1 ounce of cannabis costing €110 at intake €100 at 1-year 
(cost per joint, 39c at intake 35c at 1-year)
Crime Outcomes
There was a reduction in the percentage of participants’ involved  
in acquisitive crime, from 35% (n=21) at treatment intake to 7% 
(n=4) at 1-year.
The numbers of participants involved in the selling/supplying of drugs 
in the 90 days prior to interview decreased between treatment intake 
and 1-year (see Table 4). In addition, the proportion of participants’ 
who committed theft from a person, theft from a shop, theft from a 
vehicle, theft of a vehicle, and handling stolen goods reduced over  
this period.
Overall, a higher proportion of participants reported no criminal 
involvement in the 90 days prior to interview at 1-year (74%) 
compared to treatment intake (19%).
Table 4 Offending behaviour in the 90 days prior 
to treatment intake & 1-year interview
% committed
Intake 1-year
% n % n
Selling/supplying 49 26 11 6*
Theft from a person 15 8 2 1*
Theft from a house/
home
6 3 0 0
Theft from a shop etc. 17 9 2 1*
Theft from a vehicle 13 7 2 1*
Theft of a vehicle 15 8 2 1*
Handling stolen goods 30 16 4 2*
Fraud/forgery/
deception
9 5 0 0
Assault 6 3 4 2
Criminal damage 6 3 0 0
Soliciting 4 2 2 1
Breach of the peace 8 4 0 0
* McNemar test revealed statistically significant changes
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Risk Behaviour Outcomes
The reduction in participants’ drug use was accompanied by a 
reduction in the numbers who reported injecting drug use. At 
treatment intake 48% (n=30) of the cohort injected a drug in 
the 90 days prior to interview compared with 23% (n=14) at 
1-year. A statistically significant decrease in injecting was reported 
across two of the three most commonly injected substances; 
cocaine and heroin (see Figure 3).
Participants also reported a decrease in the frequency of injecting 
drug use, as indicated by changes in the average number of 
days and average times per day individuals reported injecting 
in the 90 days prior to treatment intake and 1-year interview. 
At treatment intake participants reported injecting on average 
18.6 days (sd=29.1) out of the previous 90, this reduced to 
6.8 days (sd=20) at 1-year follow-up. Similarly, at treatment 
intake individuals reported injecting on average 2.4 times per day 
(sd=4.7) compared with 0.9 times per day (sd=2.5) at 1-year.
Figure 3 Injecting drug use by drug type in the 90 
days prior to treatment intake & 1-year interview
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* McNemar test revealed statistically significant changes
The proportion of participants who reported an overdose in the 
previous 90 days reduced from 5% (n=3) at treatment intake to 
0% at 1-year. The death of one participant recruited within the 
detoxification modality was suspected to be due to an overdose 
(communication with family and service provider). This has yet to 
be independently confirmed.
There were no changes in participants’ injecting-related risk 
behaviours. At treatment intake low rates of borrowing, lending, 
and reusing used injecting equipment, and sharing of injecting 
paraphernalia (e.g. spoons and filters) were reported. With the 
exception of an increase in reported borrowing, these behaviours 
remained the same over time (see Table 5).
Table 5 Injecting-related risk behaviour in the 30 
days prior to treatment intake & 1-year interview
% reported
Intake 1-year
% n % n
Borrowed used needles/
syringes
0 0 4 2
Lent used needles/syringes 2 1 2 1
Reused own needles/
syringes
13 7 13 7
Used filters/spoons after 
someone
5 3 4 2
Health Outcomes
Improvements in both the physical and mental health symptoms 
of the cohort were evident over the relatively short time-period. 
The numbers of participants who reported seven of the 10 
physical health symptoms reduced from treatment intake to 1-
year (see Table 6). No increase was observed in the proportions 
reporting the remaining three symptoms; tiredness/fatigue, 
nausea, and difficulty breathing.
As expected, all the symptoms associated with opiate withdrawal 
(stomach pains, joint/bone pains, muscle pains, and tremors/
shakes) reduced from treatment intake to 1-year.
Table 6 Physical health symptoms in the 90 days 
prior to treatment intake & 1-year interview
% reported
Intake 1-year
% n % n
Poor appetite 78 46 54 32*
Tiredness/fatigue 79 46 72 42
Nausea (feeling sick) 42 25 31 18
Stomach pains 58 34 29 17*
Difficulty breathing 36 21 22 13
Chest pains 42 25 17 10*
Joint/bone pains 49 29 25 15*
Muscle pains 47 28 20 12*
Numbness/tingling 
arms/legs
36 21 14 8*
Tremors/shakes 36 21 3 2*
* McNemar test revealed statistically significant changes
Table 7 illustrates that there were reductions in the number of 
participants’ who reported suffering from five of the 10 mental 
health symptoms. Most of these reductions were in anxiety 
related symptoms (i.e. feeling tense, suddenly scared for no 
reason, nervous/shaking inside and panic attacks). Although there 
were reductions in the numbers who reported the remaining, 
largely depressive-type symptoms (i.e. feeling hopeless about the 
future, feelings of worthlessness, no interest in things, and feeling 
lonely), results were not statistically significant.
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Table 7 Mental health symptoms in the 90 days 
prior to treatment intake & 1-year interview
% reported
Intake 1-year
% n % n
Feeling tense 77 44 53 30*
Suddenly scared for no 
reason
48 28 24 14*
Feeling fearful 50 28 37 21
Nervous/shaking inside 61 34 32 18*
Panic attacks 39 22 21 12*
Feeling hopeless about 
future
64 36 45 25
Feelings of 
worthlessness
66 37 48 27
No interest in things 64 36 52 29
Feeling lonely 62 34 47 26
Thoughts of ending life 33 18 11 6*
* McNemar test revealed statistically significant changes
Service Contact
There was an increase in participants’ contact with three social 
care services (social services, employment/education services, 
and housing/homeless services) from treatment intake to 1-
year. In addition, although not statistically significant, participants’ 
reported a decrease in contact with hospital A&E departments 
and social welfare services, over the time period (see Table 8).
Table 8 Contact with health & social care services 
in the 90 days prior to treatment intake & 1-year 
interview
% reported
Intake 1-year
% n % n
Stayed overnight in 
hospital
8 5 15 9
Treated in A & E 20 12 16 10
Seen GP 36 21 47 28
Outpatient appointment 13 8 23 14
Contact with social 
services
2 1 16 10*
Employment/education 
services
13 8 57 35*
Social welfare services 49 30 36 22
Housing/homeless 
services
19 12 37 23*
* McNemar test revealed statistically significant changes
Differences Between Those Interviewed 
at 1-year and Those ‘Lost’ to Follow-up
Less than one-quarter of the cohort (23%, n=19) did not 
complete the 1-year follow-up interview. Analysis was undertaken 
to determine whether there were any differences between those 
interviewed at 1-year and those ‘lost’ to follow-up at treatment 
intake, which may bias the results in the current document.
Table 9 shows the differences (at treatment intake) in key 
variables between the two groups. Participants who were 
interviewed at 1-year were significantly more likely to have used 
both cocaine and alcohol at treatment intake, and reported using 
cocaine on significantly more days. Table 9 also shows that 
individuals followed-up were more likely to rate their need for 
treatment at intake, as being very important.
The intake characteristics and problems of participants 
interviewed at 1-year and those ‘lost’ to follow-up were compared 
using a logistic regression of key variables (age, gender, frequency 
of heroin use, quantity of heroin used, frequency of cocaine 
use, number of drugs used, number of days injecting drug use, 
frequency of alcohol use, previous treatment for drug/alcohol 
use, treatment setting).
The results showed that treatment setting and the number of 
drugs used at treatment intake had a significant effect on whether 
participants were interviewed at 1-year. In this regard, participants 
recruited in the prison setting were less likely to complete 1-year 
interview.
Table 9 Comparison of participant characteristics 
at treatment intake between those ‘lost’ to 1-year 
follow-up and those interviewed
‘Lost’ Interviewed
(n=19) (n=62)
Gender (% male) 74 77
Mean age (yrs) 25.4 26.6
Age left school (yrs) 13.8 15.3‡
On social welfare (%) 53 79
Treatment setting
 Inpatient (%) 32 63
 Outpatient (%) 21 29
 Prison (%) 47 8
Time on waiting list (wks) 10.9 6.3
Rated treatment as very 
important(%)
79 98
Used heroin last 90 days (%) 63 79
Mean days used heroin 23.0 38.3
Used cocaine last 90 days (%) 26 56*
Mean days used cocaine 4.1 12.2‡
Used alcohol last 90 days (%) 42 61
Mean days used alcohol 5.1 15.4‡
Injected last 90 days (%) 50 65
‡ Paired t-test showed statistical significance
* Chi-square test statistically significant
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Conclusion
ROSIE is the first national study to have examined 1-year treatment outcomes for opiate users. The findings presented 
in this document demonstrate that participation in a detoxification programme is followed by reduced drug use, reduced 
injecting, decreased involvement in crime, improved physical and mental health symptoms and increased contacts with 
social care services.
When compared with national and international research, the outcomes for ROSIE participants in detoxification treatment 
were good. Programme completion rates (68%) were high. Smyth et al (2005)1 reported a programme completion rate of 
42% (defined as planned discharges). Gossop et al (1986)2 reported rates of complete withdrawal varying from 81% for 
inpatient participants and 17% for outpatient participants.
The decrease in heroin use among ROSIE participants was comparable with the reductions observed in Smyth et al’s 
study. At 1-year follow-up 39% of ROSIE participants were abstinent from all drugs including prescribed methadone. 
Smyth et al (2005) reported an abstinence rate of 23%, however, this was over a longer follow-up period, 2-3 years post-
treatment intake. Within NTORS, Gossop et al (1999)3 report that in residential programmes - which included detoxification 
programmes - abstinence rates from the target drugs, heroin, non-prescribed methadone, cocaine, amphetamines and 
benzodiazepines increased from 2.5% at treatment intake to 37% at 1-year follow up and just over half were abstinent 
from illicit opiates at 1-year. Within the Australian outcome study, ATOS, 52% of those who entered a detoxification 
programme at baseline were abstinent from heroin at 1-year (Teesson et al, 2006)4. The results of the ROSIE detoxification 
cohort at 1-year follow-up compare favourably with these international results. Table 3 shows that 61% of participants 
reported not using heroin in the 90 days prior to 1-year follow-up interview.
Forty-two per cent of the ROSIE participants were on a methadone programme at 1-year follow-up. In Smyth et al (2005) 
study 57% of participants were on methadone at 2-3 years post-treatment intake. The results from the ROSIE 3-year follow-
up will provide information on whether the observed positive behaviour changes at 1-year are sustained over time.
Detoxification is not usually thought of as being treatment per se, or as being effective on its own, rather that it is part of a 
process that provides an opportunity to enable individuals to engage in further treatment such as residential rehabilitation. 
Additional analysis of the ROSIE data is needed to determine the effects of aftercare, or follow-on interventions post-
detoxification, on treatment outcomes.
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